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Abstract The Bcl-2 family of proteins that consists of anti-
apoptotic and pro-apoptotic members determines life-or-death of
a cell by controlling the release of mitochondrial apoptogenic
factors, cytochrome c and apoptosis-inducing factor (AIF), that
activate downstream executional phases, including the activation
of death proteases called caspases. Cytochrome c release is, thus,
central to apoptotic signal transduction in mammals, making
study of the mechanism for cytochrome c release a major issue.
Several models for cytochrome c release have been proposed,
including rupture of mitochondrial outer membrane and involve-
ment of a specific channel. Here, we provide an overview of
recent findings on the role of Bcl-2 family members in the life-or-
death decision of a cell.
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1. Introduction
Apoptosis is the essential physiological mechanism for se-
lective elimination of cells. It plays an integral part in a vari-
ety of biological events, including morphogenesis, the process
of cell turnover and removal of harmful cells. Apoptotic ma-
chinery can also quite easily be activated by a variety of stim-
uli such as pathological reagents that might cause various
diseases. The framework of the apoptotic signal transduction
pathway appears to consist of two parts: the private and
common. Various pro-apoptotic signals initially activate indi-
vidual stimulus-speci¢c signaling pathways which eventually
converge into a common mechanism that activates death pro-
teases called caspases [1,2]. The common mechanism of apop-
tosis is negatively regulated by several sets of genes, of which
the best characterized is the still growing bcl-2 family [3,4].
This mechanism of apoptosis appears to have been well con-
served through evolution: Caenorhabditis elegans and mam-
mals share a set of molecules that plays a key role in apop-
tosis.
Here, we illustrate the recent view of how Bcl-2 family
proteins determines life-or-death in a cell.
2. Bcl-2 family proteins as apoptosis regulators
Bcl-2 [5] was initially shown to inhibit cell death induced by
IL-3 deprivation [6] and subsequently shown to inhibit cell
death induced by various other stimuli including chemother-
apeutic agents and heat shock [7]. In recent years, it has been
well established that Bcl-2 prevents most forms of apoptotic
cell death as well as certain forms of necrotic cell death. A
large number of Bcl-2-related proteins have been isolated [3,4]
and divided into three categories (Fig. 1):
1. Anti-apoptotic members such as Bcl-2, Bcl-xL, Bcl-w, Mcl-
1, A1 (B£-1) and Boo, all of which exert anti-cell death
activity and share sequence homology, particularly within
four regions, Bcl-2 homology (BH) 1 through BH4,
although some members lack an apparent BH4 domain.
2. Pro-apoptotic members such as Bax, Bak, Bad, Mtd (Bok),
Diva, which share sequence homology in BH1, BH2 and
BH3 but not in BH4, although signi¢cant homology at
BH4 has been noticed in some members.
3. ‘BH3-only proteins’, the pro-apoptotic proteins which in-
clude Bik, Bid, Bim, Hrk (DP5), Blk and Bnip3, Bnip3L,
and share sequence homology only in BH3.
One of the unique features of Bcl-2 family proteins is het-
erodimerization between anti-apoptotic and pro-apoptotic
proteins, which is considered to inhibit the biological activity
of their partners [8,9]. This heterodimerization is mediated by
the insertion of a BH3 region of a pro-apoptotic protein into
a hydrophobic cleft composed of BH1, BH2 and BH3 from an
anti-apoptotic protein [10]. In addition to the BH1 and BH2,
the BH4 domain is required for anti-apoptotic activity [11]. In
contrast, BH3 is essential and, itself, su⁄cient for pro-apop-
totic activity [12].
In addition to the regulation of apoptosis by hetero-
dimerization of anti-apoptotic and pro-apoptotic members
of the Bcl-2 family, some protein members have been sug-
gested to regulate apoptosis independently of each other,
based on the observations with transgenic and knockout
mice [13]. This notion might be consistent with the ¢ndings
that some Bcl-2 family members such as Bcl-2, Bcl-xL, and
Bax, can form ion channels in synthetic lipid membranes [14^
17]. Although one of the BH3-only proteins, Bid, shares very
limited sequence homology with Bcl-2 and Bax which have
channel-forming ability, it has been shown that the solution
structure of Bid is strikingly similar to Bcl-xL [18^20], and Bid
indeed creates an ion channel on synthetic lipid membranes
[21]. However, it still remains to be determined whether Bcl-2
family proteins actually form ion channels in vivo and
whether these proteins regulate apoptosis via the creation of
ion channels.
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3. Prevention of the release of mitochondrial apoptogenic
factors by Bcl-2/Bcl-xL
There is accumulating evidence that the mitochondria play
an essential role in many forms of apoptosis [22] by releasing
apoptogenic factors, such as cytochrome c [23^25] and apop-
tosis-inducing factor (AIF) [26] from the intermembrane space
into the cytoplasm, which activates the downstream execu-
tional phase of apoptosis. AIF, which is a £avoprotein with
a signi¢cant homology to bacterial oxidoreductases, has an
ability to induce apoptotic morphological changes of the nu-
cleus in a caspase-independent manner [26], probably repre-
senting a minor pathway for apoptotic nuclear changes. On
the other hand, cytochrome c directly activates caspases [23]
by binding to a cytoplasmic protein Apaf-1 (Ced-4 homo-
logue) via the C-terminal WD-40 repeat domain in the pres-
ence of ATP or dATP, resulting in an oligomer complex [27]
which recruits pro-caspase-9, in turn inducing the self-cleav-
age/activation of caspase-9 [27,28].
The release of AIF is dependent upon the occurrence of
membrane permeability transition (PT)[29] characterized by
membrane potential (vi) loss [30], while cytochrome c release
can be either dependent [31,32] or independent [24,25,33] on
PT. Both Bcl-2 and Bcl-xL prevent all mitochondrial changes
including cytochrome c release and vi-loss [31,32,34]. How-
ever, Bcl-xL but probably not Bcl-2 has an additional ability
to prevent caspase activation by sequestering Apaf-1 [35,36].
Although this design is similar to the mechanism by which
CED-4 (Apaf-1 homologue) is regulated by CED-9 (Bcl-2
homologue) in C. elegans [37], the physiological role of Bcl-
2 family proteins to sequester Apaf-1 in preventing caspase
activation was recently questioned, based upon the failure to
detect a physiologically relevant level of stable interaction
between Apaf-1 and Bcl-2/Bcl-xL [38].
As for the process of cytochrome c release, three models
have been proposed. One is that cytochrome c release is medi-
ated by physical rupture of the mitochondrial outer mem-
brane, resulting from mitochondrial swelling (Fig. 2a) [39,
40], although previous studies suggest that mitochondrial
swelling rarely accompanies apoptosis. The other models in-
volve cytochrome c release through speci¢c channels (Fig.
2b,c).
4. Mechanism for cytochrome c release through a channel
A system with isolated mitochondria and recombinant Bcl-2
family proteins has proven very useful for understanding
mechanisms of how Bcl-2 family proteins regulate apoptotic
mitochondrial changes. It has been shown that addition of
recombinant Bax or Bak to isolated mitochondria induces
cytochrome c release and vi-loss [31,32,41]. Because these
e¡ects can be inhibited by cyclosporin A [31,32], which targets
mitochondrial cyclophilin D, the cyclosporin A-sensitive PT
pore has been implicated in Bax/Bak-mediated cytochrome c
release and vi-loss. Consistently, Bax/Bak-mediated cyto-
chrome c release and vi-loss are reportedly inhibited by other
PT inhibitors such as bonkrekic acid that targets ANT and
calcium depletion [31,32,34]. There were controversial reports
that Bax/Bak-mediated cytochrome c release is independent of
vi-loss, but this discrepancy arises from the di¡erence in ex-
perimental conditions used as discussed below. Thus, it is fair
to say that Bax/Bak-mediated cytochrome c release and vi-
loss can at least be regulated by the PT pore. The PT pore is
an oligo-protein channel, consisting of porin (or the voltage-
dependent anion channel, VDAC) on the outer membrane,
adenine nucleotide translocator (ANT) on the inner mem-
brane, and matrix protein cyclophilin D [42]. Bax has been
shown to interact with VDAC [32,43] and ANT [43,44].
VDAC has recently been determined to be one of the func-
tional targets for Bcl-2 family proteins [43] : Bcl-xL closes the
VDAC channel on liposomes, whereas Bax/Bak appears to
open the channel so that cytochrome c passes though the
channel (Fig. 2c). An essential role of VDAC in Bax/Bak-
mediated cytochrome c was con¢rmed by the observation
that Bax/Bak induces cytochrome c release from wild type
but not VDAC-1-de¢cient yeast mitochondria [43]. How
does Bax/Bak open the VDAC pore size? Bax/Bak might in-
duce a conformational change of VDAC to form a larger
Fig. 1. Schematic drawing of Bcl-2 and related proteins. BH1 to
BH4 are conserved sequence motifs. Several functional domains of
Bcl-2 are shown (see text). K1^K7 Indicate helices identi¢ed in Bcl-
xL, in which a core of two hydrophobic helices K5 and K6 is sur-
rounded by ¢ve amphipathic helices. The region between K1 and
K2 is called a loop which appears to have a regulatory role. A
membrane-anchoring domain is not carried by all members of the
family.
Fig. 2. Mechanisms for cytochrome c release during apoptosis.
Three mechanisms are proposed by which cytochrome c is released
during apoptosis: (A) physical rupture of the outer membrane, (B)
a channel formed by pro-apoptotic Bcl-2 family members such as
Bax, (C) a novel channel formed by VDAC and pro-apoptotic Bcl-2
family members such as Bax. Molecular nature of the novel VDAC-
Bax channel is not determined but might be a composite channel.
Once cytochrome c is in the cytoplasm, it activates caspase(s).
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pore or be involved in forming a larger pore together with
VDAC.
Kroemer’s group has described that Bax modulates ANT
activity [44], although how Bax actually induces cytochrome c
release by interacting with ANT was not su⁄ciently ex-
plained. It may be presumed that enhanced opening of
ANT induced by Bax might result in mitochondrial swelling,
leading to outer membrane rupture. Studies with yeast mu-
tants revealed that none of the three ANTs is essential for
Bax/Bak-mediated cytochrome c release from isolated mito-
chondria [45], which would exclude ANTs altogether in Bax/
Bak-mediated cytochrome c release.
It was shown that unlike Bax and Bak, BH3-only proteins
such as Bid and Bik do not directly a¡ect VDAC activity on
liposomes [46], suggesting that the BH3-only proteins function
through pro-apoptotic Bcl-2 family members such as Bax and
Bak or through a totally di¡erent mechanism. The former
possibility might be supported by the ¢ndings that Bid induces
a conformational change of Bax and Bak, as assessed by an
increased accessibility of some antibodies to Bax and Bak
which would otherwise be non-reactive [47]. However, the
following might support the latter possibility: Bax/Bak-in-
duced cytochrome c release is signi¢cantly di¡erent from
Bid (or Bik)-mediated cytochrome c release. Notable dissim-
ilarities are the concomitant occurrence of vi-loss with Bax/
Bak-mediated but not Bid/Bik-mediated cytochrome c release
and the inhibition of Bax/Bak-mediated but not Bid/Bik-medi-
ated cytochrome c release by PT inhibitors and respiratory
chain inhibitors [46].
Besides its e¡ect on VDAC in cytochrome c release, Bax
itself has been shown to form a large channel with a con-
ductance at nS level on the planar lipid bilayer [17], which
might be large enough for cytochrome c to pass through (Fig.
2b), but can not be determined until experimentally demon-
strated.
5. Potential loss and VDAC
In addition to being an essential factor in cytochrome c
release, VDAC has been shown to also be required for apop-
totic vi-loss [43] whereas ANTs are again dispensable [45].
Since VDAC is a component of the PT pore, VDAC probably
communicates with other channels on the inner membrane:
opening VDAC su⁄ciently for cytochrome c release might
trigger the opening of inner membrane channels, resulting in
vi-loss. Given that Bax/Bak directly interacts with ANT and
that there seem to be several ANT-like proteins in the mito-
chondria, such as the Pi/OH3 antiporter and uncoupling pro-
teins, these channels might be directly involved in vi-loss.
Since vi-loss is Ca2-dependent, the Ca2 depletion prevents
vi-loss, which might explain occurrence of Bax/Bak-induced
cytochrome c release without vi-loss [31,33]. Whether or not
Ca2 is required for cytochrome c release seems to depend on
di¡erent mitochondrial preparations and experimental condi-
tions that might a¡ect the activity or structure of the PT pore.
Ca2 eventually induces PT, probably resulting in the en-
hancement of cytochrome c release at least with isolated mi-
tochondria. However, it should be noted that, in cells, the
interaction of Bax with VDAC might not trigger all of what
is seen in the isolated mitochondria during PT. For example,
swelling might be just an extreme reaction of the in vitro PT.
Since VDAC and ANT are in the PT pore complex, an ANT
inhibitor bonkrekic acid (assumed to close ANT channel)
would conceivably prevent VDAC opening, thereby inhibiting
cytochrome c release. Alternatively, Bax might induce vi-loss
by a totally di¡erent mechanism, which might be indirectly
regulated by the PT pore.
6. Bcl-2 family proteins: a possible convergence point for
various life-death signals
In living cells, apoptotic mitochondrial changes are pre-
dominantly prevented by anti-apoptotic Bcl-2 members. Dur-
ing apoptosis, the pro-apoptotic Bcl-2 family members are
activated, apparently undergoing a conformational change
[47], possibly leading to the exposure of the pro-apoptotic
BH3 domain through several mechanisms, including dephos-
phorylation (e.g. Bad) [48] and proteolytic cleavage by cas-
pases (e.g. Bid) [49,50]. Dephosphorylation by phosphase(s)
such as calcineurin also frees Bad from cytoplasmic 14-3-3
to translocate to the mitochondria. In addition to Bid and
Bad, Bax and Bim, which mainly localize in the cytoplasm
in living cells, translocate to the mitochondria to exert pro-
apoptotic activity during apoptosis [51^53]. Cytoplasmic Bim
(inactive) is bound to LC8 dynein light chain and thereby
sequestered to the microtubules-associated dynein motor com-
plex [54]. Bax translocation to the mitochondria involves ho-
modimerization. Di¡erent pro-apoptotic members play a ma-
jor role in initiating cytochrome c release in certain settings of
apoptosis : Bid is implicated in Fas-mediated apoptosis, Bax
in DNA damage-induced apoptosis and neurotrophin depri-
vation-induced death and Bad in lymphokine deprivation-in-
duced cell death in certain cells.
Given that the activities of anti-apoptotic and pro-apop-
totic members of the Bcl-2 family are regulated by di¡erent
mechanisms, such as various binding proteins with apparently
distinct functions and post-translational modi¢cations, such
as phosphorylation [55] and proteolytic cleavage [56], the
Bcl-2 family might constitute a convergence point for various
apoptosis-regulating signals [4]. The presence of a number of
BH3-only proteins with a high degree of heterogeneity might
Fig. 3. Convergence of di¡erent apoptotic signals into the mitochon-
dria via divergent pro-apoptotic members of the Bcl-2 family. Dif-
ferent pro-apoptotic Bcl-2 family members might receive di¡erent
death-signals via various regions and transduce the signals to the
mitochondria via the conserved BH3 domains.
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suggest that they receive di¡erent death signals through het-
erogeneous regions of the proteins and that all information
converges to the mitochondria via a common BH3 domain
(Fig. 3). Thus, the presence of heterogeneity and a common
element such as the BH3 domain seem to make it possible for
a variety of death signals to be integrated into a common
pathway on the mitochondria.
7. In summary
Apoptotic mitochondrial changes, including release of cyto-
chrome c and potential loss leading to AIF release, are central
to apoptotic signal transduction. Anti-apoptotic members and
pro-apoptotic members interact with each other to suppress
the activity of their partners and also function independently
to directly regulate these apoptogenic mitochondrial changes
by interacting with VDAC and possibly other mitochondrial
proteins as well. Thus, Bcl-2 family proteins constitute a ma-
jor life-or-death decision point on the mitochondria.
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